Clinical Trial Update: Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy [NA]

View source ↗

Summary

A completed trial evaluating two oral doses of NP031112 versus placebo in mild-to-moderate Progressive Supranuclear Palsy. The study assessed safety, tolerabili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• NP031112

Snippet

Sponsor: Noscira SA | Conditions: Progressive Supranuclear Palsy | NA | Status: COMPLETED